107 related articles for article (PubMed ID: 4053264)
1. Regional targeting of bisantrene by directed intravascular precipitation.
Kovach JS; Buck M; Tsukamoto T; Odegaard A; Lieber MM
Cancer Chemother Pharmacol; 1985; 15(3):192-5. PubMed ID: 4053264
[TBL] [Abstract][Full Text] [Related]
2. Directed intravascular precipitation of bisantrene for pelvic malignant lesions: preclinical studies.
Lieber MM; Welch TJ; Johnson CM; Farrow GM; Buck M; Kovach JS
Mayo Clin Proc; 1986 Mar; 61(3):173-9. PubMed ID: 3945117
[TBL] [Abstract][Full Text] [Related]
3. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride.
Lu K; Savaraj N; Yap BS; Feun LG; Umsawasdi T; Loo TL
Cancer Chemother Pharmacol; 1986; 16(2):156-9. PubMed ID: 3948302
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.
Weiss GR; Hersh M; Kuhn JG; Ludden TM; von Hoff DD; Kisner DL; Pirtle TE
Cancer Chemother Pharmacol; 1985; 15(2):144-8. PubMed ID: 4017163
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
Yap BS; Yap HY; Blumenschein GR; Bedikian AY; Pocelinko R; Bodey GP
Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the pharmacokinetics of bisantrene (NSC-337766).
Kuhn JG; Ludden TM; Myers JW; Von Hoff DD
Invest New Drugs; 1983; 1(3):253-7. PubMed ID: 6678875
[TBL] [Abstract][Full Text] [Related]
9. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
10. Tissue deposition of bisantrene in B16 melanoma tumor-bearing mice.
Nicolau G; Wu WH; McWilliams W; Citarella RV; Durr FE
Cancer Invest; 1986; 4(1):25-8. PubMed ID: 3955418
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro metabolism of the new anticancer drug bisantrene.
Peng YM; Alberts DS; Davis TP
Cancer Chemother Pharmacol; 1985; 14(1):15-20. PubMed ID: 3965156
[TBL] [Abstract][Full Text] [Related]
12. Blood and tissue concentrations of Bisantrene measured by a simple fluorometric assay.
Buck M; Kovach JS
Cancer Chemother Pharmacol; 1985; 15(1):40-3. PubMed ID: 4006048
[TBL] [Abstract][Full Text] [Related]
13. [Tissue levels of pirarubicin (THP) in dogs following intra-arterial infusion].
Sumiyoshi Y; Yokota K; Akiyama M; Kawaoto H; Kosugi I
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1621-6. PubMed ID: 1872619
[TBL] [Abstract][Full Text] [Related]
14. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.
Bowden GT; Roberts R; Alberts DS; Peng YM; Garcia D
Cancer Res; 1985 Oct; 45(10):4915-20. PubMed ID: 4027978
[TBL] [Abstract][Full Text] [Related]
15. Light, fluorescent, and electron microscopic analysis of cultured breast tumor cells (T-47D) treated with 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride.
Tseng MT; Safa AR
Cancer Res; 1983 Dec; 43(12 Pt 1):5910-4. PubMed ID: 6640539
[TBL] [Abstract][Full Text] [Related]
16. Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride.
Powis G
J Chromatogr; 1981 Dec; 226(2):514-20. PubMed ID: 7320182
[No Abstract] [Full Text] [Related]
17. N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity.
Murdock KC; Lee VJ; Citarella RV; Durr FE; Nicolau G; Kohlbrenner M
J Med Chem; 1993 Jul; 36(15):2098-101. PubMed ID: 8340913
[TBL] [Abstract][Full Text] [Related]
18. Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote.
Dorr RT; Peng YM; Alberts DS
Invest New Drugs; 1984; 2(4):351-7. PubMed ID: 6096286
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of accumulation of the antitumor protein antibiotic neocarzinostatin in bladder tissue: intravenous administration, urinary excretion, and absorption into bladder tissue.
Maeda H; Sakamoto S; Ogata J
Antimicrob Agents Chemother; 1977 Jun; 11(6):941-5. PubMed ID: 141906
[TBL] [Abstract][Full Text] [Related]
20. DNA-binding preferences of bisantrene analogues: relevance to the sequence specificity of drug-mediated topoisomerase II poisoning.
Sissi C; Bolgan L; Moro S; Zagotto G; Bailly C; Menta E; Capranico G; Palumbo M
Mol Pharmacol; 1998 Dec; 54(6):1036-45. PubMed ID: 9855632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
